| Bioactivity | Cavrotolimod is an immunostimulatory spherical nucleic acid (SNA) modified with type B CpG oligonucleotides designed to agonize TLR9 and elicit immune responses useful in oncology applications. |
| Name | Cavrotolimod |
| CAS | 2378664-12-9 |
| Formula | C300H423N71O161P26S23 |
| Molar Mass | 9142.88 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Daniel WL, Lorch U, Mix S, Bexon AS. A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation. Front Immunol. 2022;13:1073777. [2]. Rubatto M, Sciamarrelli N, Borriello S, et al. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. Front Med (Lausanne). 2023;9:959289. |
Cavrotolimod
CAS: 2378664-12-9 F: C300H423N71O161P26S23 W: 9142.88
Cavrotolimod is an immunostimulatory spherical nucleic acid (SNA) modified with type B CpG oligonucleotides designed to
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.